CN101287764A - 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 - Google Patents
特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 Download PDFInfo
- Publication number
- CN101287764A CN101287764A CNA2006800379242A CN200680037924A CN101287764A CN 101287764 A CN101287764 A CN 101287764A CN A2006800379242 A CNA2006800379242 A CN A2006800379242A CN 200680037924 A CN200680037924 A CN 200680037924A CN 101287764 A CN101287764 A CN 101287764A
- Authority
- CN
- China
- Prior art keywords
- seq
- antibody
- describing
- cell
- people
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001225 therapeutic effect Effects 0.000 title description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title 1
- 239000010931 gold Substances 0.000 title 1
- 229910052737 gold Inorganic materials 0.000 title 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims abstract description 134
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims abstract description 134
- 238000000034 method Methods 0.000 claims abstract description 67
- 239000012634 fragment Substances 0.000 claims abstract description 65
- 239000000427 antigen Substances 0.000 claims abstract description 62
- 102000036639 antigens Human genes 0.000 claims abstract description 62
- 108091007433 antigens Proteins 0.000 claims abstract description 62
- 230000027455 binding Effects 0.000 claims abstract description 47
- 230000002147 killing effect Effects 0.000 claims abstract description 16
- 244000309715 mini pig Species 0.000 claims abstract description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 105
- 239000002773 nucleotide Substances 0.000 claims description 43
- 125000003729 nucleotide group Chemical group 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 230000000295 complement effect Effects 0.000 claims description 20
- 238000009396 hybridization Methods 0.000 claims description 14
- 241000282693 Cercopithecidae Species 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 13
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 241001515942 marmosets Species 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 7
- 102000018358 immunoglobulin Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 241000173347 Tonsilla Species 0.000 claims 1
- 210000004958 brain cell Anatomy 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 210000000663 muscle cell Anatomy 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000004988 splenocyte Anatomy 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 75
- 108090000623 proteins and genes Proteins 0.000 description 59
- 235000018102 proteins Nutrition 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 51
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 18
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 16
- 238000005406 washing Methods 0.000 description 12
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000009260 cross reactivity Effects 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000282566 Macaca arctoides Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000003146 transient transfection Methods 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000282553 Macaca Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 229960002378 oftasceine Drugs 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 101150044508 key gene Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940049547 paraxin Drugs 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000006035 Tryptophane Substances 0.000 description 2
- -1 Xie Ansuan Chemical compound 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012882 sequential analysis Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000000074 ADP-ribosyl Cyclase Human genes 0.000 description 1
- 108010080394 ADP-ribosyl Cyclase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010060935 Alloimmunisation Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010573 double replacement reaction Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000009432 framing Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000005501 phase interface Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
Abstract
Description
抗体(Fab或IgG1) | BIACORE(Fab)KD[nM]a | FACS Scatchard(IgG1)bKD[nM] |
MOR03076 | 440/596 | n.d. |
MOR03078 | n.d. | n.d. |
MOR03081 | 416/450 | 2.5 |
MOR03085 | 122 | 10 |
MOR03086 | 30 | n.d. |
MOR03087 | 17/38 | 5 |
MOR03088 | 95 | n.d. |
MOR03089 | 340 | n.d. |
MOR03101 | 314 | n.d. |
MOR03102 | 64 | 5 |
MOR03127 | 168(54)c | n.d. |
MOR03128 | 117/84d | n.d. |
MOR03129 | 43 | n.d. |
MOR03130 | n.d. | n.d. |
MOR03131 | 451 | n.d. |
嵌合OKT10 | n.d. | 8.28 |
引物# | 序列(5’->3’) |
MTE001 | ATG GCC AAC TGC GAG TTC AGC(SEQ ID NO:123) |
MTE002rev | TCA GAT CTC AGA TGT GCA AGA TGA ATC(SEQ ID NO:124) |
MTE004 | TT GGT ACC AGG TGG CGC CAG CAG TG(SEQ ID NO:125) |
MTE006 | TT GGT ACC ATG GCC AAC TGC GAG(SEQ ID NO:126) |
MTE007rev | CCG ATA TCA*GAT CTC AGA TGT GCA AGA TG(SEQ ID NO:127) |
MTE009rev | CCG ATA TC GAT CTC AGA TGT GCA AGA TG(SEQ ID NO:128) |
Claims (44)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310494874.2A CN103554259B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
CN201510918061.0A CN106434683B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72529705P | 2005-10-12 | 2005-10-12 | |
US60/725,297 | 2005-10-12 | ||
PCT/EP2006/009889 WO2007042309A2 (en) | 2005-10-12 | 2006-10-12 | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310494874.2A Division CN103554259B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
CN201310495574.6A Division CN103554260A (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
CN201510918061.0A Division CN106434683B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101287764A true CN101287764A (zh) | 2008-10-15 |
CN101287764B CN101287764B (zh) | 2013-11-13 |
Family
ID=37467440
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510918061.0A Active CN106434683B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
CN201310494874.2A Active CN103554259B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
CN2006800379242A Active CN101287764B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
CN201310495574.6A Pending CN103554260A (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510918061.0A Active CN106434683B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
CN201310494874.2A Active CN103554259B (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310495574.6A Pending CN103554260A (zh) | 2005-10-12 | 2006-10-12 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
Country Status (29)
Country | Link |
---|---|
US (6) | US8088896B2 (zh) |
EP (3) | EP3284756B1 (zh) |
JP (2) | JP5362359B2 (zh) |
KR (4) | KR101512853B1 (zh) |
CN (4) | CN106434683B (zh) |
AR (2) | AR055191A1 (zh) |
AU (1) | AU2006301446B2 (zh) |
BR (1) | BRPI0618399B1 (zh) |
CA (1) | CA2625681C (zh) |
CY (1) | CY1119722T1 (zh) |
DK (1) | DK2860192T3 (zh) |
ES (1) | ES2653664T3 (zh) |
HK (2) | HK1122822A1 (zh) |
HR (1) | HRP20171978T1 (zh) |
HU (1) | HUE035250T2 (zh) |
IL (1) | IL190665B (zh) |
LT (1) | LT2860192T (zh) |
ME (1) | ME02886B (zh) |
NO (1) | NO344961B1 (zh) |
NZ (1) | NZ566915A (zh) |
PL (1) | PL2860192T3 (zh) |
PT (1) | PT2860192T (zh) |
RS (1) | RS56677B1 (zh) |
RU (1) | RU2425841C2 (zh) |
SG (1) | SG10201400973XA (zh) |
SI (1) | SI2860192T1 (zh) |
TW (1) | TWI428444B (zh) |
WO (1) | WO2007042309A2 (zh) |
ZA (1) | ZA200803208B (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103118706A (zh) * | 2010-09-27 | 2013-05-22 | 莫佛塞斯公司 | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl |
CN103513040A (zh) * | 2013-10-16 | 2014-01-15 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
CN104937099A (zh) * | 2012-11-09 | 2015-09-23 | 基因先端领域株式会社 | 用于治疗癌症的抗adam28抗体 |
CN107207596A (zh) * | 2014-11-04 | 2017-09-26 | 格兰马克药品股份有限公司 | Cd3/cd38 t 细胞重靶向异源二聚体免疫球蛋白及其生产方法 |
CN109293773A (zh) * | 2018-09-25 | 2019-02-01 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
US10329358B2 (en) | 2015-03-06 | 2019-06-25 | Genefrontier Corporation | Anti-human membrane-type ADAM28 antibody |
CN111886251A (zh) * | 2017-12-14 | 2020-11-03 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
AU2006301446B2 (en) | 2005-10-12 | 2012-06-07 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
PE20120259A1 (es) | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
NZ592151A (en) | 2008-12-12 | 2012-10-26 | Boehringer Ingelheim Int | Anti-igf antibodies |
US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
US9238689B2 (en) | 2011-07-15 | 2016-01-19 | Morpho Sys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) |
US20130122005A1 (en) | 2011-10-27 | 2013-05-16 | Paul Adam | Anticancer combination therapy |
EP3559049A4 (en) | 2011-10-28 | 2019-12-04 | Teva Pharmaceuticals Australia Pty Ltd | POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF |
US9051365B2 (en) | 2011-12-21 | 2015-06-09 | Novartis Ag | Antibodies that bind factor P |
AU2013253581B2 (en) | 2012-04-23 | 2019-05-16 | Genefrontier Corporation | Anti-human CD69 antibody, and use thereof for medical purposes |
PT2900232T (pt) | 2012-09-25 | 2018-02-09 | Morphosys Ag | Combinações e suas utilizações |
EP2914302B1 (en) | 2012-11-05 | 2017-01-04 | MorphoSys AG | Radiolabelled antibody and uses thereof |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
PL2968555T3 (pl) * | 2013-03-13 | 2020-11-16 | Sanofi | Kompozycje zawierające przeciwciała anty-cd38 i karfilzomib |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
AU2013388126B2 (en) * | 2013-04-29 | 2019-03-07 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
JP5892117B2 (ja) * | 2013-07-17 | 2016-03-23 | 横河電機株式会社 | フィールド機器及び通信システム |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
UA119167C2 (uk) | 2014-03-28 | 2019-05-10 | Зенкор, Інк. | Біспецифічне антитіло, яке зв'язується з cd38 та cd3 |
UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
TWI645230B (zh) | 2014-08-03 | 2018-12-21 | 帕戈技術股份有限公司 | 穿戴式照相機系統與用於將照相機系統或其他電子裝置附接至穿戴式製品之設備及方法 |
MY192918A (en) | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
KR102639037B1 (ko) | 2014-10-29 | 2024-02-20 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 인터페론 α2b 변이체 |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
CN107406512A (zh) | 2014-11-26 | 2017-11-28 | Xencor公司 | 结合cd3和cd38的异二聚体抗体 |
EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
EP3280443B1 (en) | 2015-04-08 | 2022-08-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
US10533057B2 (en) | 2015-05-13 | 2020-01-14 | Morphosys Ag | Treatment for multiple myeloma (MM) |
AU2016264725B2 (en) | 2015-05-20 | 2021-05-27 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
JP6816038B2 (ja) | 2015-06-22 | 2021-01-20 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体及びサバイビン阻害剤による血液悪性疾患の併用療法 |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
AU2016281717B2 (en) | 2015-06-24 | 2022-07-28 | Janssen Biotech, Inc. | Immune modulation and treatment of solid tumors with antibodies that specifically bind CD38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
MA53356B1 (fr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations |
KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
JP7362250B2 (ja) | 2016-03-04 | 2023-10-17 | モルフォシス・アーゲー | 多発性骨髄腫におけるmタンパク質反応の臨床評価 |
KR102405278B1 (ko) | 2016-04-22 | 2022-06-07 | 악셀레론 파마 인코포레이티드 | Alk7 결합 단백질 및 이들의 용도 |
MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
EP3474895A1 (en) | 2016-06-28 | 2019-05-01 | UMC Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
EP3487506A1 (en) | 2016-07-20 | 2019-05-29 | Hybrigenics SA | Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
AU2018280868A1 (en) | 2017-06-08 | 2020-01-02 | Black Belt Therapeutics Limited | CD38 modulating antibody |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
US11236173B2 (en) | 2017-08-16 | 2022-02-01 | Black Belt Therapeutics Limited | CD38 antibody |
JP2020533362A (ja) | 2017-09-13 | 2020-11-19 | テネオバイオ, インコーポレイテッド | エクト酵素に結合する重鎖抗体 |
EP3692066A2 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
CA3079963A1 (en) | 2017-10-25 | 2019-05-02 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
KR20200076732A (ko) | 2017-11-03 | 2020-06-29 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd38-지시된 키메라 항원 수용체 작제물 |
CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
BR112020018927A2 (pt) | 2018-03-21 | 2021-01-05 | ALX Oncology Inc. | Anticorpos contra proteína alfa reguladora de sinal e métodos de uso |
EP3793606A4 (en) | 2018-05-16 | 2022-08-31 | Janssen Biotech, Inc. | METHODS OF TREATMENT OF CANCER AND ENHANCEMENT OF THE EFFECTIVENESS OF T-CELL REFERRING THERAPEUTICS |
EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
TW202016151A (zh) | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
EP3810655A4 (en) * | 2018-06-20 | 2022-03-16 | Sorrento Therapeutics, Inc. | ANTIBODY VARIANT BINDING TO CD38 |
MA53123A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
MA53122A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
CA3111651A1 (en) | 2018-09-11 | 2020-03-19 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
JP2022512722A (ja) | 2018-10-17 | 2022-02-07 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体の皮下投与を提供する方法 |
BR112021000173A2 (pt) | 2018-10-26 | 2021-05-04 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd38 |
SG11202104092UA (en) | 2018-11-13 | 2021-05-28 | Janssen Biotech Inc | Control of trace metals during production of anti-cd38 antibodies |
SG11202104012QA (en) | 2018-12-14 | 2021-05-28 | Morphosys Ag | Antibody formulations |
AU2020211728A1 (en) * | 2019-01-23 | 2021-08-12 | Encefa | CD31 competitors and uses thereof |
AU2020242228A1 (en) | 2019-03-15 | 2021-07-22 | Morphosys Ag | Anti-CD38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
AU2020299600A1 (en) * | 2019-07-03 | 2022-01-06 | Crystal Bioscience Inc. | Anti-CD38 antibody and methods of use thereof |
CN114786713A (zh) * | 2019-09-18 | 2022-07-22 | 动量制药公司 | 与靶向CD38的工程化Fc抗原结合结构域构建体相关的组合物和方法 |
TW202128756A (zh) | 2019-10-02 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
GB201916150D0 (en) | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
JPWO2021112196A1 (zh) * | 2019-12-05 | 2021-06-10 | ||
EP4077391A1 (en) | 2019-12-18 | 2022-10-26 | Teneofour, Inc. | Heavy chain antibodies binding to cd38 |
MX2022008050A (es) | 2020-01-16 | 2022-07-27 | Genmab As | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
TW202214303A (zh) | 2020-05-19 | 2022-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之結合分子 |
WO2022002065A1 (zh) * | 2020-06-30 | 2022-01-06 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
CN111808193B (zh) * | 2020-06-30 | 2022-04-05 | 源道隆(苏州)医学科技有限公司 | 可结合人cd38的纳米抗体及其应用 |
IL300666A (en) | 2020-08-19 | 2023-04-01 | Xencor Inc | ANTI–CD28 COMPOSITIONS |
JP2023546228A (ja) | 2020-10-21 | 2023-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 眼の疾患の処置のための二重特異性抗VEGF及び抗TrkB結合分子 |
AU2022208200A1 (en) | 2021-01-14 | 2023-07-20 | Morphosys Ag | Anti-cd38 antibodies and their uses |
US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗cd38抗體 |
WO2022192403A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
TW202317625A (zh) | 2021-06-17 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 新穎三特異性結合分子 |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
IL310372A (en) | 2021-07-28 | 2024-03-01 | Genentech Inc | IL15/IL15R alpha heterodimeric FC-fused proteins for the treatment of blood cancer |
US20230136301A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
WO2023143547A1 (zh) * | 2022-01-30 | 2023-08-03 | 百奥泰生物制药股份有限公司 | 抗cd28抗体及其应用 |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
WO2023240135A2 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | Bifunctional chelators and conjugates |
US20240052065A1 (en) | 2022-07-15 | 2024-02-15 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
WO2024095173A1 (en) | 2022-11-02 | 2024-05-10 | Janssen Biotech, Inc. | Methods of treating cancers |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
WO1987004154A1 (en) * | 1986-01-03 | 1987-07-16 | The University Of Melbourne | Melphalan derivatives |
SU1595902A1 (ru) * | 1988-06-30 | 1990-09-30 | Всесоюзный онкологический научный центр АМН СССР | Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к антигену СД38 кортикальных тимоцитов |
US5156951A (en) * | 1989-07-13 | 1992-10-20 | Becton Dickinson And Company | Detecting immunological changes in HIV infected patient samples |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
AU6123894A (en) | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
US6555324B1 (en) | 1993-11-04 | 2003-04-29 | Becton Dickinson & Company | Method to distinguish hematopoietic progenitor cells |
US20020164788A1 (en) * | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
GB9424449D0 (en) * | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
RU2205874C2 (ru) | 1995-05-11 | 2003-06-10 | Апплайд Резеч Системз Арс Холдинг Н.В. | Нуклеотидная последовательность, способная ингибировать активность il-6, плазмидный вектор для трансфекции в клетки млекопитающих, нуклеотидная последовательность, используемая при терапии, фармацевтическая композиция (варианты) |
ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
US5594116A (en) | 1995-11-08 | 1997-01-14 | Promega Corporation | Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay |
WO1998016245A1 (fr) * | 1996-10-15 | 1998-04-23 | Shionogi & Co., Ltd. | Procede de determination d'un auto-anticorps |
AU770718B2 (en) | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
US7223397B1 (en) * | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
GB9903664D0 (en) | 1999-02-17 | 1999-04-14 | Isis Innovation | Adjuvant and cell maturation agent |
JP2000316578A (ja) | 1999-05-12 | 2000-11-21 | Bml Inc | 糖尿病発症危険因子の検出方法 |
IL142025A0 (en) | 1999-07-20 | 2002-03-10 | Morphosys Ag | Novel methods for displaying (poly) peptides/proteins on bacteriophage particles via disulfide bonds |
US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
CA2424643A1 (en) | 2000-10-17 | 2002-04-25 | Trudeau Institute, Inc. | Cd38 modulated chemotaxis |
US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
US6892140B1 (en) | 2000-11-27 | 2005-05-10 | Enteron, Inc. | Immunogenic cancer peptides and uses thereof |
US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
US20040081981A1 (en) | 2001-01-31 | 2004-04-29 | Toru Egashira | Method of detecting risk factor for onset of diabetes |
ATE484522T1 (de) | 2001-04-24 | 2010-10-15 | Bayer Corp | Menschliche antikörper gegen timp-1 |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
WO2003033538A1 (fr) | 2001-10-15 | 2003-04-24 | Kirin Beer Kabushiki Kaisha | Anticorps anti-hlr-dr |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003241103A1 (en) | 2002-04-23 | 2003-11-10 | Umberto Dianzani | Compositions containing anti-hiv peptides and methods of use |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
EP1689435A4 (en) | 2003-10-22 | 2007-10-03 | Univ Rochester | ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS |
EP1720907B1 (en) * | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
WO2006125640A2 (en) * | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
ES2331891T3 (es) | 2004-02-13 | 2010-01-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Vairantes de procesamiento de cd38 y usos de las mismas. |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
JP2008535853A (ja) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌関連遺伝子 |
AU2006301446B2 (en) | 2005-10-12 | 2012-06-07 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
CN101883846A (zh) | 2007-10-01 | 2010-11-10 | 科德克希思公司 | 用于生成氮杂环丁酮的还原酶多肽 |
AU2010308030B2 (en) | 2009-10-12 | 2014-05-29 | Pfizer Inc. | Cancer treatment |
KR101912957B1 (ko) * | 2010-09-27 | 2018-10-29 | 모르포시스 아게 | 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉 |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
PT2900232T (pt) * | 2012-09-25 | 2018-02-09 | Morphosys Ag | Combinações e suas utilizações |
EP2914302B1 (en) * | 2012-11-05 | 2017-01-04 | MorphoSys AG | Radiolabelled antibody and uses thereof |
US11920830B1 (en) | 2022-11-11 | 2024-03-05 | Russell Dwayne Mcnally | Tool and method for cleaning and draining a water heater |
-
2006
- 2006-10-12 AU AU2006301446A patent/AU2006301446B2/en active Active
- 2006-10-12 CA CA2625681A patent/CA2625681C/en active Active
- 2006-10-12 PL PL14196972T patent/PL2860192T3/pl unknown
- 2006-10-12 NZ NZ566915A patent/NZ566915A/en unknown
- 2006-10-12 SG SG10201400973XA patent/SG10201400973XA/en unknown
- 2006-10-12 CN CN201510918061.0A patent/CN106434683B/zh active Active
- 2006-10-12 AR ARP060104476A patent/AR055191A1/es active IP Right Grant
- 2006-10-12 CN CN201310494874.2A patent/CN103554259B/zh active Active
- 2006-10-12 HU HUE14196972A patent/HUE035250T2/hu unknown
- 2006-10-12 EP EP17193089.4A patent/EP3284756B1/en active Active
- 2006-10-12 WO PCT/EP2006/009889 patent/WO2007042309A2/en active Application Filing
- 2006-10-12 EP EP14196972.5A patent/EP2860192B1/en active Active
- 2006-10-12 TW TW095137628A patent/TWI428444B/zh active
- 2006-10-12 KR KR1020087011301A patent/KR101512853B1/ko active IP Right Grant
- 2006-10-12 DK DK14196972.5T patent/DK2860192T3/en active
- 2006-10-12 KR KR1020147020460A patent/KR101574920B1/ko active IP Right Grant
- 2006-10-12 LT LTEP14196972.5T patent/LT2860192T/lt unknown
- 2006-10-12 KR KR1020137033870A patent/KR101472250B1/ko active IP Right Grant
- 2006-10-12 BR BRPI0618399-9A patent/BRPI0618399B1/pt active IP Right Grant
- 2006-10-12 CN CN2006800379242A patent/CN101287764B/zh active Active
- 2006-10-12 PT PT141969725T patent/PT2860192T/pt unknown
- 2006-10-12 JP JP2008534940A patent/JP5362359B2/ja active Active
- 2006-10-12 RU RU2008111882/10A patent/RU2425841C2/ru active
- 2006-10-12 EP EP06806243A patent/EP1945671A2/en not_active Withdrawn
- 2006-10-12 KR KR1020157034098A patent/KR20150139636A/ko not_active Application Discontinuation
- 2006-10-12 RS RS20171300A patent/RS56677B1/sr unknown
- 2006-10-12 ME MEP-2017-289A patent/ME02886B/me unknown
- 2006-10-12 US US12/089,806 patent/US8088896B2/en active Active
- 2006-10-12 ES ES14196972.5T patent/ES2653664T3/es active Active
- 2006-10-12 SI SI200632232T patent/SI2860192T1/en unknown
- 2006-10-12 CN CN201310495574.6A patent/CN103554260A/zh active Pending
-
2008
- 2008-04-07 IL IL190665A patent/IL190665B/en active IP Right Grant
- 2008-04-11 ZA ZA200803208A patent/ZA200803208B/xx unknown
- 2008-04-25 NO NO20081972A patent/NO344961B1/no unknown
- 2008-12-30 HK HK08114074.2A patent/HK1122822A1/xx unknown
-
2011
- 2011-11-08 US US13/291,473 patent/US8486394B2/en active Active
-
2012
- 2012-11-08 JP JP2012246686A patent/JP5752667B2/ja active Active
-
2013
- 2013-06-14 US US13/918,199 patent/US9193799B2/en active Active
-
2014
- 2014-07-31 HK HK14107873.1A patent/HK1194398A1/zh unknown
-
2015
- 2015-10-08 US US14/877,958 patent/US10184005B2/en active Active
-
2016
- 2016-07-26 AR ARP160102271A patent/AR105490A2/es not_active Application Discontinuation
-
2017
- 2017-12-19 CY CY20171101331T patent/CY1119722T1/el unknown
- 2017-12-20 HR HRP20171978TT patent/HRP20171978T1/hr unknown
-
2018
- 2018-09-07 US US16/125,307 patent/US11059902B2/en active Active
-
2021
- 2021-06-09 US US17/343,163 patent/US11939395B2/en active Active
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103118706A (zh) * | 2010-09-27 | 2013-05-22 | 莫佛塞斯公司 | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl |
CN103118706B (zh) * | 2010-09-27 | 2016-05-18 | 莫佛塞斯公司 | 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl |
CN104937099A (zh) * | 2012-11-09 | 2015-09-23 | 基因先端领域株式会社 | 用于治疗癌症的抗adam28抗体 |
US9845364B2 (en) | 2012-11-09 | 2017-12-19 | Genefrontier Corporation | Anti-ADAM28 antibody for treating cancer |
US10556967B2 (en) | 2012-11-09 | 2020-02-11 | Genefrontier Corporation | Anti-ADAM28 antibody for treating cancer |
CN103513040A (zh) * | 2013-10-16 | 2014-01-15 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
CN103513040B (zh) * | 2013-10-16 | 2015-03-11 | 常晓天 | 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用 |
CN107207596A (zh) * | 2014-11-04 | 2017-09-26 | 格兰马克药品股份有限公司 | Cd3/cd38 t 细胞重靶向异源二聚体免疫球蛋白及其生产方法 |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
US10329358B2 (en) | 2015-03-06 | 2019-06-25 | Genefrontier Corporation | Anti-human membrane-type ADAM28 antibody |
CN111886251A (zh) * | 2017-12-14 | 2020-11-03 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
CN109293773A (zh) * | 2018-09-25 | 2019-02-01 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101287764B (zh) | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 | |
US20180215832A1 (en) | Anti-cd38 human antibodies and uses therefor | |
JP5926568B2 (ja) | 抗cd38ヒト抗体及びその用途 | |
CN1976950B (zh) | 抗cd38人抗体及其用途 | |
EP2799451A1 (en) | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 | |
US9200061B2 (en) | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i | |
MX2008004897A (es) | Generacion y perfilado de anticuerpos terapeuticos derivados de hucal gold totalmente humanos especificos para cd38 humano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1122822 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1122822 Country of ref document: HK |
|
CP02 | Change in the address of a patent holder |
Address after: Praneger, Germany Patentee after: Morphosys AG Address before: Martins Reed Germany Patentee before: Morphosys AG |
|
CP02 | Change in the address of a patent holder |